Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
George N. Ioannou, MD, MS
Professor & Director of Hepatology,
VA Puget Sound Health Care System
Biography

Dr. Ioannou is a professor based at the VA Puget Sound Health Care System. He specializes in hepatitis C, non-alcoholic fatty liver disease, iron deficiency and iron overload.

Recent Publications
Displaying 20 Most Recent Publications from PubMed

August 2019. Prevalence of Hepatitis B Virus Exposure in the Veterans Health Administration and Association With Military-related Risk Factors. Beste LA, Ioannou GN, Chang MF, Forsberg CW, Korpak AM, Boyko EJ, Sporleder JL, Smith NL, Maynard C, Chartier M, Dominitz JA; VA Cooperative Study Group #488. Clin Gastroenterol Hepatol. 2019 Aug 5. pii: S1542-3565(19)30845-6. doi: 10.1016/j.cgh.2019.07.056. [Epub ahead of print]

July 2019. Perioperative Evaluation and Management of Patients with Cirrhosis: Risk Assessment, Surgical Outcomes, and Future Directions. Newman KL, Johnson KM, Cornia PB, Wu P, Itani K, Ioannou GN. Clin Gastroenterol Hepatol. 2019 Jul 31. pii: S1542-3565(19)30840-7. doi: 10.1016/j.cgh.2019.07.051. [Epub ahead of print]

July 2019. Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Gastroenterology. 2019 Jul 30. pii: S0016-5085(19)41137-2. doi: 10.1053/j.gastro.2019.07.040. [Epub ahead of print]

July 2019. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette C, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Clin Gastroenterol Hepatol. 2019 Jul 26. pii: S1542-3565(19)30786-4. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print]

July 2019. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores. Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Gastroenterology. 2019 Jul 26. pii: S0016-5085(19)41130-X. doi: 10.1053/j.gastro.2019.07.033. [Epub ahead of print]

June 2019. Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals. Ioannou GN, Green PK, Berry K, Graf SA. Hepatol Commun. 2019 Jun 11;3(8):1124-1136. doi: 10.1002/hep4.1389. eCollection 2019 Aug.

May 2019. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. Ioannou GN, Green P, Kerr KF, Berry K. J Hepatol. 2019 May 27. pii: S0168-8278(19)30291-0. doi: 10.1016/j.jhep.2019.05.008. [Epub ahead of print]

May 2019. Editorial: benefits of HCV eradication beyond the liver. Ioannou GN. Aliment Pharmacol Ther. 2019 May;49(10):1364-1365. doi: 10.1111/apt.15261.

April 2019. Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. Ioannou GN, Landis CS, Jin GY, Haigh WG, Farrell GC, Kuver R, Lee SP, Savard C. Hepatol Commun. 2019 Apr 1;3(6):776-791. doi: 10.1002/hep4.1348. eCollection 2019 Jun.

February 2019. Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy. Su F, Ioannou GN. Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):6-12. doi: 10.1002/cld.781. eCollection 2019 Jan.

February 2019. Reply. Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. Gastroenterology. 2019 Feb 19. pii: S0016-5085(19)30398-1. doi: 10.1053/j.gastro.2019.02.024. [Epub ahead of print]

February 2019. For Whom is Hepatocellular Carcinoma Surveillance after Sustained Virologic Response Cost Effective? Singal AG, Ioannou GN. Clin Gastroenterol Hepatol. 2019 Feb 14. pii: S1542-3565(19)30183-1. doi: 10.1016/j.cgh.2019.02.020. [Epub ahead of print]

January 2019. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence after Liver Transplantation: The RH-IML Classification. Vutien P, Dodge J, Bambha KM, Nordstrom EM, Gralla J, Campbell K, Levek C, Nydam T, Fix O, Ioannou G, Biggins SW. Liver Transpl. 2019 Jan 31. doi: 10.1002/lt.25422. [Epub ahead of print]

January 2019. Machine learning models to predict disease progression among veterans with hepatitis C virus. Konerman MA, Beste LA, Van T, Liu B, Zhang X, Zhu J, Saini SD, Su GL, Nallamothu BK, Ioannou GN, Waljee AK. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019.

December 2018. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Su F, Ioannou GN. Curr Hepatol Rep. 2018 Dec;17(4):377-384. doi: 10.1007/s11901-018-0424-8. Epub 2018 Sep 20.

October 2018. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Liang JQ, Teoh N, Xu L, Pok S, Li X, Chu ESH, Chiu J, Dong L, Arfianti E, Haigh WG, Yeh MM, Ioannou GN, Sung JJY, Farrell G, Yu J. Nat Commun. 2018 Oct 26;9(1):4490. doi: 10.1038/s41467-018-06931-6.

October 2018. What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection? Ioannou GN, Feld JJ. Gastroenterology. 2018 Oct 24. pii: S0016-5085(18)35166-7. doi: 10.1053/j.gastro.2018.10.033. [Epub ahead of print]

October 2018. Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment". Ioannou GN. J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445-0. doi: 10.1016/j.jhep.2018.09.026. [Epub ahead of print]

September 2018. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. PLoS One. 2018 Sep 27;13(9):e0204412. doi: 10.1371/journal.pone.0204412. eCollection 2018.

August 2018. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. Mun EJ, Green P, Berry K, Ioannou GN. Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242. [Epub ahead of print]

August 2018. Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C. Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287-6. doi: 10.1016/j.jhep.2018.07.024. [Epub ahead of print]

July 2018. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-related Mortality in Patients with Cirrhosis. Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. Gastroenterology. 2018 Jul 5. pii: S0016-5085(18)34721-8. doi: 10.1053/j.gastro.2018.06.079. [Epub ahead of print]

May 2018. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. Owens MD, Ioannou GN, Tsui JL, Edelman JE, Greene PA, Williams EC. Drug Alcohol Depend. 2018 May 8;188:79-85. doi: 10.1016/j.drugalcdep.2018.03.047. [Epub ahead of print]

February 2018. Mouse Models Of Nonalcoholic Steatohepatitis: A Reflection On Recent Literature. Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, Yu J, Teoh NC, Farrell GC. J Gastroenterol Hepatol. 2018 Feb 9. doi: 10.1111/jgh.14122. [Epub ahead of print]

December 2017. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. Yoo W, Gjuka D, Stevenson HL, Song X, Shen H, Yoo SY, Wang J, Fallon M, Ioannou GN, Harrison SA, Beretta L. PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017.

November 2017. Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C. Johnson K, Green PK, Ioannou GN. J Viral Hepat. 2017 Nov;24(11):966-975. doi: 10.1111/jvh.12731. Epub 2017 Jul 12.

October 2017. Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. Patankar JV, Wong CK, Morampudi V, Gibson WT, Vallance B, Ioannou GN, Hayden M. Am J Physiol Endocrinol Metab. 2017 Oct 24:ajpendo.00172.2017. doi: 10.1152/ajpendo.00172.2017.

September 2017. Reply to Letters to the Editor Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292-4. doi: 10.1016/j.jhep.2017.09.011. [Epub ahead of print]

September 2017. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Ioannou GN, Green PK, Berry K. J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273-0. doi: 10.1016/j.jhep.2017.08.030. [Epub ahead of print]

September 2017. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN. Diabetes Care. 2017 Sep;40(9):1173-1180. doi: 10.2337/dc17-0485. Epub 2017 Jun 28.

Contact Info
Education

M.D., Oxford University, Oxford, UK

Internship, Duke University, Durham, NC

Residency, Duke University, Durham, NC

FAASLD, American Association for the Study of Liver Diseases

©2016-2018 University of Washington Division of Gastroenterology
1959 NE Pacific St., Box 356424, Seattle, WA 98195-6424
Contact Us | Privacy | Terms | Copyright & Disclaimer